GSK and Bharat Biotech Partner to Develop Shigella Vaccine:

Bharat Biotech and pharmaceutical giant GSK have entered into a collaboration to advance the development of GSK’s Shigella vaccine candidate, altSonflex1-2-3. Bharat Biotech will oversee Phase 3 trials, regulatory submissions, and mass manufacturing, while GSK will contribute to the clinical design, seek external funding, and support commercialization.